Imperial College London
Portrait Picture

DrCarolynMillar

Faculty of Medicine, Department of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 2153c.millar

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Batty:2017:10.1111/bjh.14543,
author = {Batty, P and Austin, SK and Khair, K and Millar, CM and Palmer, B and Rangarajan, S and Stuempel, J-P and Thanigaikumar, M and Yee, TT and Hart, DP},
doi = {10.1111/bjh.14543},
journal = {British Journal of Haematology},
pages = {796--804},
title = {Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A},
url = {http://dx.doi.org/10.1111/bjh.14543},
volume = {176},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Inhibitor formation in non-severe haemophilia A is a life-long risk and associated with morbidity and mortality. There is a paucity of data to understand real-world inhibitor screening practice. We evaluated the treatment burden, haemostatic strategies, F8 genotyping and inhibitor screening practices in non-severe haemophilia A in seven London haemophilia centres. In the 2-year study period, 44% (377/853) patients received at least one haemostatic treatment. Seventy-nine percent of those treated (296/377) received factor VIII (FVIII) concentrate. F8 genotype was known in 88% (331/377) of individuals. Eighteen per cent (58/331) had ‘high-risk’ F8 genotypes. In patients with ‘standard-risk’ F8 genotypes treated on-demand with FVIII concentrate, 51·3% episodes (243/474) were screened within 1 year. However, poor screening compliance was observed after ‘high-risk’ treatment episodes. In patients with ‘standard-risk’ F8 genotypes, 12·3% (28/227) of treatment episodes were screened in the subsequent 6 weeks after surgery or a bleed requiring ≥5 exposure days. Similarly, in the context of ‘high-risk’ F8 genotypes after any FVIII exposure, only 13·6% (12/88) of episodes were screened within 6 weeks. Further study is required to assess optimal practice of inhibitor screening in non-severe haemophilia A to inform subsequent clinical decisions and provide more robust prevalence data to further understand the underlying immunological mechanism.
AU  - Batty,P
AU  - Austin,SK
AU  - Khair,K
AU  - Millar,CM
AU  - Palmer,B
AU  - Rangarajan,S
AU  - Stuempel,J-P
AU  - Thanigaikumar,M
AU  - Yee,TT
AU  - Hart,DP
DO  - 10.1111/bjh.14543
EP  - 804
PY  - 2017///
SN  - 1365-2141
SP  - 796
TI  - Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A
T2  - British Journal of Haematology
UR  - http://dx.doi.org/10.1111/bjh.14543
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000395191500013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/52846
VL  - 176
ER  -
Download